Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trial
Phase 3positiveivonescimabPositive
AI Analysis
Summary
Akeso announced positive updated Phase 3 data for ivonescimab, a PD-1xVEGF bispecific, meeting the overall survival endpoint in certain lung cancer patients, restoring investor confidence after a prior interim readout.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Updated Phase 3 data for ivonescimab met overall survival bar in certain lung cancer patients
Importance:8/10
Sentiment:
0.70
Phase 3lung cancerbispecificPD-1xVEGFoverall survivalpositive data
Read the original article
Published by Endpoints News on September 3, 2026 11:12 AM